Intensity Therapeuticsincis A Late Stage Clinical Biotechnology Company Based In Westportconnecticutthe Company Is Focused On Developing Innovative Treatments For Cancerparticularly Through A New Immune Based Approach To Target Solid Tumor Cancerstheir Goal Is To Enhance The Quality And Duration Of Patientslives By Utilizing Scientific Advancements In Localized Cancer Reduction And Immune Activation The Company Employs Its Proprietary Dfuserxa Discovery Platform To Create Unique Drug Formulationstheir Lead Product Candidateint230 6Combines Two Established Anticancer Agentscisplatin And Vinblastinewith An Amphiphilic Moleculethis Formulation Is Designed To Directly Kill Cancer Cells And Stimulate An Immune Response That Can Address Non Injected Tumors And Micro Metastasesintensity Therapeutics Is Currently Conducting Several Clinical Trials For Int230 6Including A Phase 3 Trial In Metastatic Sarcoma And Plans For A Phase 2 3 Program In Triple Negative Breast Cancer
No conferences found for this company.
| Company Name | Intensity Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
